Early tolerance outcomes of stereotactic hypofractionated accelerated radiation therapy concomitant with pelvic node irradiation in high-risk prostate cancer Journal Article
| Authors: | Pinitpatcharalert, A.; Happersett, L.; Kollmeier, M.; McBride, S.; Gorovets, D.; Tyagi, N.; Varghese, M.; Zelefsky, M. J. |
| Article Title: | Early tolerance outcomes of stereotactic hypofractionated accelerated radiation therapy concomitant with pelvic node irradiation in high-risk prostate cancer |
| Abstract: | Purpose: This study aimed to evaluate the toxicity of prostate and pelvic lymph node stereotactic body radiation therapy (SBRT) for high-risk prostate cancer. Methods and Materials: Twenty-three patients with high-risk or lymph node-positive prostate cancer were treated with SBRT that delivered 37.5 to 40 Gy in 5 fractions to the prostate and seminal vesicles, with concomitant treatment of the pelvic nodes to 25 Gy. In general, patients received neoadjuvant, concurrent, and adjuvant androgen deprivation therapy for a duration of 18 months. Toxicities were evaluated with the Common Terminology Criteria for Adverse Events, version 3.0. The median follow-up was 19 months (range, 3-48 months). Results: Acute grade 1 gastrointestinal (GI) toxicities were noted in 2 patients (9.1%). No patient experienced acute grade ≥2 GI toxicity. Acute genitourinary (GU) grade 1, 2, and 3 toxicities were observed in 7 patients (31.8%), 8 patients (36.4%), and 1 patient (4.5%), respectively. Late grade 2 GI and GU toxicities were observed in 2 patients (9.1%) and 6 patients (27.3%), respectively. No late grade ≥3 GI toxicity was noted. Late grade ≥3 GU (hemorrhagic cystitis) was noted in 1 patient (4.5%), which responded to laser fulguration. Conclusions: SBRT with pelvic lymph node radiation therapy was feasible and well tolerated. The incidence of grade ≥3 GU and GI toxicities was uncommon. Continued follow-up will be required to determine the long-term safety and efficacy of this approach for high-risk patients. © 2018 |
| Journal Title: | Advances in Radiation Oncology |
| Volume: | 4 |
| Issue: | 2 |
| ISSN: | 2452-1094 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2019-04-01 |
| Start Page: | 337 |
| End Page: | 344 |
| Language: | English |
| DOI: | 10.1016/j.adro.2018.12.001 |
| PROVIDER: | scopus |
| PMCID: | PMC6460324 |
| PUBMED: | 31011679 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 May 2019 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work